Loading
A phase 3 trial of Gemcitabine, Vinorelbine, Paclitaxel / nab-paclitaxel, Pemetrexed, H101 oncolytic adenovirus, Recombinant human endostatin and Cisplatin in Non-small-cell lung cancer, run by Xinqiao Hospital of Chongqing, with a status the registry has not verified recently.
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients is a phase 3 interventional study registered as NCT02579564 by Xinqiao Hospital of Chongqing, with 134 participants planned, started 2016-10 and due to reach its primary completion in 2018-06. Interventions recorded: Gemcitabine, Vinorelbine, Paclitaxel, Pemetrexed, Oncorine, Endostar, Cisplatin. Conditions recorded: Malignant Hydrothorax, Non Small Cell Lung Cancer.
Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Recombinant human endostatin, Non-small-cell lung cancer and the tag pipeline.
Shares Recombinant human endostatin, Non-small-cell lung cancer and the tag pipeline.
Shares Vinorelbine, Paclitaxel / nab-paclitaxel, Cisplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Gemcitabine, Cisplatin and the tag pipeline.
Shares H101 oncolytic adenovirus and the tag pipeline.
Shares Pemetrexed, Gemcitabine, Cisplatin, Non-small-cell lung cancer and the tag pipeline.
Shares H101 oncolytic adenovirus and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Non-small-cell lung cancer and the tag pipeline.